Patterns of Benzodiazepine Use and Excess Risk of All-Cause Mortality in the Elderly: A Nationwide Cohort Study.


Journal

Drug safety
ISSN: 1179-1942
Titre abrégé: Drug Saf
Pays: New Zealand
ID NLM: 9002928

Informations de publication

Date de publication:
01 2021
Historique:
pubmed: 31 10 2020
medline: 12 2 2022
entrez: 30 10 2020
Statut: ppublish

Résumé

Despite the risks associated with their use, benzodiazepines remain used more widely than wisely. In this context, a better understanding of how their patterns of use can be associated with an increased risk of death appears essential. Indeed, the studies that investigated this association so far are inconsistent and question the influence of potential biases. The objective of this study was to investigate the association of various patterns of benzodiazepine use with all-cause mortality. A nationwide cohort of non-prevalent benzodiazepine users aged ≥ 65 years was identified using French healthcare insurance system claims databases. Exposure to benzodiazepines considered short-term, chronic (defined as a cumulated ≥ 6-month period over the previous 12 months), ongoing, and discontinued use. Using a Cox model, adjusted hazard ratios for all-cause mortality were estimated according to benzodiazepine patterns of use; exposure and confounders were treated as time-dependent variables. In the cohort of 54,958 individuals aged ≥ 65 years, adjusted hazard ratios for all-cause mortality and benzodiazepines were 2.26 (95% confidence interval 1.96-2.61) for short-term use, 3.86 (3.04-4.90) for chronic use-discontinued, and 3.05 (2.17-4.29) for chronic use-ongoing. At age 80 years, these were 1.62 (1.48-1.79), 2.00 (1.82-2.19) and 1.13 (1.02-1.26), respectively. Adjusted hazard ratios show similar decreases with age for all patterns of benzodiazepine use. These findings confirm the existence of an excess risk of mortality associated with benzodiazepine use and provide pattern- and age-specific estimates. Higher risks were observed for patients aged < 80 years, short-term use, or chronic use recently interrupted. If the two latter can relate to an indication bias, the associations found for ongoing chronic use and short-term use conversely support a potential causal hypothesis.

Identifiants

pubmed: 33125663
doi: 10.1007/s40264-020-00992-7
pii: 10.1007/s40264-020-00992-7
doi:

Substances chimiques

Benzodiazepines 12794-10-4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

53-62

Références

Sonnenberg CM, Bierman EJM, Deeg DJH, Comijs HC, van Tilburg W, Beekman ATF. Ten-year trends in benzodiazepine use in the Dutch population. Soc Psychiatry Psychiatr Epidemiol. 2012;47:293–301.
doi: 10.1007/s00127-011-0344-1
Huerta C, Abbing-Karahagopian V, Requena G, Oliva B, Alvarez Y, Gardarsdottir H, et al. Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross-national descriptive study from the PROTECT-EU Project. Pharmacoepidemiol Drug Saf. 2016;25(Suppl. 1):56–655.
doi: 10.1002/pds.3825
Agence nationale de sécurité du médicament, et des produits de santé. Etat des lieux en 2013 de la consommation des benzodiazépines en France: point d’information. 2013. https://ansm.sante.fr/S-informer/points-d-information-points-d-information/etat-des-lieux-en-2013-de-la-consommation-des-benzodiazepines-en-France-point-d-information . Accessed 11 Aug 2020.
Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiatry. 2015;72:136–42.
doi: 10.1001/jamapsychiatry.2014.1763
Bénard-Laribière A, Noize P, Pambrun E, Bazin F, Verdoux H, Tournier M, et al. Comorbidities and concurrent medications increasing the risk of adverse drug reactions: prevalence in French benzodiazepine users. Eur J Clin Pharmacol. 2016;72:869–76.
doi: 10.1007/s00228-016-2044-y
Drummer OH, Gerostamoulos J, Batziris H, Chu M, Caplehorn J, Robertson MD, et al. The involvement of drugs in drivers of motor vehicles killed in Australian road traffic crashes. Accid Anal Prev. 2004;36:239–48.
doi: 10.1016/S0001-4575(02)00153-7
Pariente A, Dartigues J-F, Benichou J, Letenneur L, Moore N, Fourrier-Réglat A. Benzodiazepines and injurious falls in community dwelling elders. Drugs Aging. 2008;25:61–70.
doi: 10.2165/00002512-200825010-00007
Orriols L, Luxcey A, Contrand B, Gadegbeku B, Delorme B, Tricotel A, et al. Road traffic crash risk associated with benzodiazepine and z-hypnotic use after implementation of a colour-graded pictogram: a responsibility study. Br J Clin Pharmacol. 2016;82:1625–35.
doi: 10.1111/bcp.13075
Née M, Avalos M, Luxcey A, Contrand B, Salmi L-R, Fourrier-Réglat A, et al. Prescription medicine use by pedestrians and the risk of injurious road traffic crashes: a case-crossover study. PLoS Med. 2017;14:e1002347.
doi: 10.1371/journal.pmed.1002347
Wu C-S, Wang S-C, Chang I-S, Lin K-M. The association between dementia and long-term use of benzodiazepine in the elderly: nested case-control study using claims data. Am J Geriatr Psychiatry. 2009;17:614–20.
doi: 10.1097/JGP.0b013e3181a65210
Billioti de Gage S, Moride Y, Ducruet T, Kurth T, Verdoux H, Tournier M, et al. Benzodiazepine use and risk of Alzheimer’s disease: case-control study. BMJ. 2014;349:g5205.
doi: 10.1136/bmj.g5205
Gomm W, von Holt K, Thomé F, Broich K, Maier W, Weckbecker K, et al. Regular benzodiazepine and Z-substance use and risk of dementia: an analysis of German claims data. J Alzheimers Dis. 2016;54:801–8.
doi: 10.3233/JAD-151006
Zhong G, Wang Y, Zhang Y, Zhao Y. Association between benzodiazepine use and dementia: a meta-analysis. PLoS ONE. 2015;10:e0127836.
doi: 10.1371/journal.pone.0127836
Chen P-L, Lee W-J, Sun W-Z, Oyang Y-J, Fuh J-L. Risk of dementia in patients with insomnia and long-term use of hypnotics: a population-based retrospective cohort study. PLoS ONE. 2012;7:e49113.
doi: 10.1371/journal.pone.0049113
Billioti de Gage S, Bégaud B, Bazin F, Verdoux H, Dartigues J-F, Pérès K, et al. Benzodiazepine use and risk of dementia: prospective population based study. BMJ. 2012;345:e6231.
doi: 10.1136/bmj.e6231
Wu C-S, Ting T-T, Wang S-C, Chang I-S, Lin K-M. Effect of benzodiazepine discontinuation on dementia risk. Am J Geriatr Psychiatry. 2011;19:151–9.
doi: 10.1097/JGP.0b013e3181e049ca
Lagnaoui R, Bégaud B, Moore N, Chaslerie A, Fourrier A, Letenneur L, et al. Benzodiazepine use and risk of dementia: a nested case-control study. J Clin Epidemiol. 2002;55:314–8.
doi: 10.1016/S0895-4356(01)00453-X
Patorno E, Glynn RJ, Levin R, Lee MP, Huybrechts KF. Benzodiazepines and risk of all cause mortality in adults: cohort study. BMJ. 2017;358:j2941.
doi: 10.1136/bmj.j2941
Vinkers DJ, Gussekloo J, van der Mast RC, Zitman FG, Westendorp RGJ. Benzodiazepine use and risk of mortality in individuals aged 85 years or older. JAMA. 2003;290:2942–3.
doi: 10.1001/jama.290.22.2942
Palmaro A, Moulis G, Despas F, Dupouy J, Lapeyre-Mestre M. Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies. Fundam Clin Pharmacol. 2016;30:616–24.
doi: 10.1111/fcp.12214
Winkelmayer WC, Mehta J, Wang PS. Benzodiazepine use and mortality of incident dialysis patients in the United States. Kidney Int. 2007;72:1388–93.
doi: 10.1038/sj.ki.5002548
Lan T-Y, Zeng Y-F, Tang G-J, Kao H-C, Chiu H-J, Lan T-H, et al. The use of hypnotics and mortality: a population-based retrospective cohort study. PLoS ONE. 2015;10:e0145271.
doi: 10.1371/journal.pone.0145271
Weich S, Pearce HL, Croft P, Singh S, Crome I, Bashford J, et al. Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study. BMJ. 2014;348:g1996.
doi: 10.1136/bmj.g1996
Kripke DF, Klauber MR, Wingard DL, Fell RL, Assmus JD, Garfinkel L. Mortality hazard associated with prescription hypnotics. Biol Psychiatry. 1998;43:687–93.
doi: 10.1016/S0006-3223(97)00292-8
Jaussent I, Ancelin M-L, Berr C, Pérès K, Scali J, Besset A, et al. Hypnotics and mortality in an elderly general population: a 12-year prospective study. BMC Med. 2013;11:212.
doi: 10.1186/1741-7015-11-212
Mokhar A, Tillenburg N, Dirmaier J, Kuhn S, Härter M, Verthein U. Potentially inappropriate use of benzodiazepines and z-drugs in the older population-analysis of associations between long-term use and patient-related factors. PeerJ. 2018;6:e4614.
doi: 10.7717/peerj.4614
Maree RD, Marcum ZA, Saghafi E, Weiner DK, Karp JF. A systematic review of opioid and benzodiazepine misuse in older adults. Am J Geriatr Psychiatry. 2016;24:949–63.
doi: 10.1016/j.jagp.2016.06.003
Tuppin P, de Roquefeuil L, Weill A, Ricordeau P, Merlière Y. French national health insurance information system and the permanent beneficiaries sample. Rev Epidemiol Sante Publique. 2010;58:286–90.
doi: 10.1016/j.respe.2010.04.005
Bezin J, Girodet P-O, Rambelomanana S, Touya M, Ferreira P, Gilleron V, et al. Choice of ICD-10 codes for the identification of acute coronary syndrome in the French hospitalization database. Fundam Clin Pharmacol. 2015;29:586–91.
doi: 10.1111/fcp.12143
Bezin J, Duong M, Lassalle R, Droz C, Pariente A, Blin P, et al. The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26:954–62.
doi: 10.1002/pds.4233
Duong M, Abouelfath A, Lassalle R, Droz C, Blin P, Moore N. Coronary events after dispensing of ibuprofen: a propensity score-matched cohort study versus paracetamol in the French nationwide claims database sample. Drug Saf. 2018;41:1049–58.
doi: 10.1007/s40264-018-0686-7
Bongue B, Laroche ML, Gutton S, Colvez A, Guéguen R, Moulin JJ, et al. Potentially inappropriate drug prescription in the elderly in France: a population-based study from the French National Insurance Healthcare system. Eur J Clin Pharmacol. 2011;67:1291–9.
doi: 10.1007/s00228-011-1077-5
Suissa S. Immeasurable time bias in observational studies of drug effects on mortality. Am J Epidemiol. 2008;168:329–35.
doi: 10.1093/aje/kwn135
Neutel CI, Patten SB. Risk of suicide attempts after benzodiazepine and/or antidepressant use. Ann Epidemiol. 1997;7:568–74.
doi: 10.1016/S1047-2797(97)00126-9
Bannay A, Chaignot C, Blotière P-O, Basson M, Weill A, Ricordeau P, et al. The best use of the Charlson Comorbidity Index with electronic health care database to predict mortality. Med Care. 2016;54:188–94.
doi: 10.1097/MLR.0000000000000471
Johnson CF, Barnsdale LR, McAuley A. Investigating the role of benzodiazepines in drug-related mortality: a systematic review undertaken on behalf of the Scottish National Forum on Drug-Related Deaths. Edinburgh: NHS Health Scotland; 2016.
Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167:492–9.
doi: 10.1093/aje/kwm324
Fukuhara S, Green J, Albert J, Mihara H, Pisoni R, Yamazaki S, et al. Symptoms of depression, prescription of benzodiazepines, and the risk of death in hemodialysis patients in Japan. Kidney Int. 2006;70:1866–72.
doi: 10.1038/sj.ki.5001832
Donnelly K, Bracchi R, Hewitt J, Routledge PA, Carter B. Benzodiazepines, Z-drugs and the risk of hip fracture: a systematic review and meta-analysis. PLoS ONE. 2017;12:e0174730.
doi: 10.1371/journal.pone.0174730
EMPOWER trial: empowering older adults to reduce benzodiazepine use. 2016. https://deprescribing.org/news/empower-trial-empowering-older-adults-to-reduce-benzodiazepine-use/ . Accessed 16 Apr 2020.
Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58:323–37.
doi: 10.1016/j.jclinepi.2004.10.012
Noize P, Bazin F, Dufouil C, Lechevallier-Michel N, Ancelin M-L, Dartigues J-F, et al. Comparison of health insurance claims and patient interviews in assessing drug use: data from the Three-City (3C) Study. Pharmacoepidemiol Drug Saf. 2009;18:310–9.
doi: 10.1002/pds.1717

Auteurs

Clément Mathieu (C)

Univ. Bordeaux, INSERM, BPH, U1219, Team Pharmacoepidemiology, Univ. Bordeaux, F-33000, Bordeaux, France.

Pierre Joly (P)

Univ. Bordeaux, INSERM, BPH, U1219, Team Biostatistics, Univ. Bordeaux, F-33000, Bordeaux, France.

Hélène Jacqmin-Gadda (H)

Univ. Bordeaux, INSERM, BPH, U1219, Team Biostatistics, Univ. Bordeaux, F-33000, Bordeaux, France.

Mathilde Wanneveich (M)

Univ. Bordeaux, INSERM, BPH, U1219, Team Biostatistics, Univ. Bordeaux, F-33000, Bordeaux, France.

Bernard Bégaud (B)

Univ. Bordeaux, INSERM, BPH, U1219, Team Pharmacoepidemiology, Univ. Bordeaux, F-33000, Bordeaux, France.
CHU Bordeaux, Pôle de Santé Publique, Centre de Pharmacovigilance de Bordeaux, Service de Pharmacologie Médicale, 33000, Bordeaux, France.

Antoine Pariente (A)

Univ. Bordeaux, INSERM, BPH, U1219, Team Pharmacoepidemiology, Univ. Bordeaux, F-33000, Bordeaux, France. antoine.pariente@u-bordeaux.fr.
CHU Bordeaux, Pôle de Santé Publique, Centre de Pharmacovigilance de Bordeaux, Service de Pharmacologie Médicale, 33000, Bordeaux, France. antoine.pariente@u-bordeaux.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH